CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 113 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2022. The put-call ratio across all filers is 1.24 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $120,142 | -27.7% | 5,503,498 | +5.3% | 0.02% | -21.7% |
| Q2 2023 | $166,097 | +41.9% | 5,224,800 | +8.9% | 0.02% | +27.8% |
| Q1 2023 | $117,066 | -22.7% | 4,799,707 | -0.1% | 0.02% | -25.0% |
| Q4 2022 | $151,537 | -99.9% | 4,804,594 | +0.7% | 0.02% | +9.1% |
| Q3 2022 | $134,775,000 | -19.0% | 4,769,074 | -24.3% | 0.02% | +4.8% |
| Q2 2022 | $166,464,000 | -26.6% | 6,295,908 | -2.8% | 0.02% | -8.7% |
| Q1 2022 | $226,795,000 | +16.6% | 6,478,010 | +8.0% | 0.02% | +27.8% |
| Q4 2021 | $194,550,000 | +12.9% | 6,000,922 | +2.7% | 0.02% | +12.5% |
| Q3 2021 | $172,302,000 | +102.1% | 5,840,731 | +75.5% | 0.02% | +100.0% |
| Q2 2021 | $85,248,000 | +82.6% | 3,327,411 | -2.1% | 0.01% | +60.0% |
| Q1 2021 | $46,680,000 | -13.6% | 3,399,888 | +0.2% | 0.01% | -16.7% |
| Q4 2020 | $54,003,000 | – | 3,392,133 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |